Jason H. Tay
Calgary, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications
Autologous stem cell transplantation for the treatment of MGRS (monoclonal gammopathy of renal significance): experience from the University of Calgary.
Journal: Leukemia & lymphoma
Published: December 10, 2025
A Multicenter, Feasibility Study Exploring Self-Administration of Chemotherapy in the Home Environment: The EASE Study.
Journal: The Annals of pharmacotherapy
Published: December 08, 2025
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.
Journal: Current oncology (Toronto, Ont.)
Published: October 31, 2024
Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.
Journal: Current oncology (Toronto, Ont.)
Published: August 22, 2024
Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years.
Journal: Canadian journal of kidney health and disease
Published: August 21, 2024
Characterizing sexuality and assessing predictors of sexual satisfaction in patients with multiple myeloma and other hematological cancers.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: June 19, 2024
Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.
Journal: Transplantation and cellular therapy
Published: April 01, 2024
Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC).
Journal: Leukemia & lymphoma
Published: December 06, 2023
A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma.
Journal: The oncologist
Published: October 29, 2023
Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary.
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 30, 2023
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone.
Journal: Clinical lymphoma, myeloma & leukemia
Published: August 19, 2022
Last Updated: 09/26/2026